What is HC Wainwright’s Forecast for VKTX FY2026 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Viking Therapeutics in a report issued on Thursday, October 29th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of ($5.51) for the year, down from their previous estimate of ($4.74). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($5.26) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q4 2026 earnings at ($1.48) EPS and FY2027 earnings at ($5.99) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, October 28th. The biotechnology company reported ($1.55) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.49). During the same period last year, the company posted ($0.81) EPS.

Several other research analysts have also recently issued reports on the company. UBS Group started coverage on Viking Therapeutics in a report on Wednesday, October 14th. They issued a “buy” rating and a $94.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Thursday, October 15th. Morgan Stanley reissued an “overweight” rating on shares of Viking Therapeutics in a research note on Tuesday, September 22nd. Oppenheimer set a $120.00 target price on Viking Therapeutics in a report on Tuesday, September 22nd. Finally, Truist Financial cut their target price on Viking Therapeutics from $87.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Viking Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $93.36.

Viking Therapeutics Trading Down 2.8%

Shares of NASDAQ:VKTX opened at $26.09 on Monday. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of -4.83 and a beta of 0.79. Viking Therapeutics has a 1-year low of $23.82 and a 1-year high of $43.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.27 and a current ratio of 7.27. The company has a 50 day moving average price of $30.23 and a 200 day moving average price of $32.36.

Hedge Funds Weigh In On Viking Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC increased its stake in shares of Viking Therapeutics by 11.3% during the 3rd quarter. Parallel Advisors LLC now owns 15,403 shares of the biotechnology company’s stock worth $502,000 after purchasing an additional 1,570 shares during the last quarter. Kestra Advisory Services LLC raised its holdings in shares of Viking Therapeutics by 12.3% during the 3rd quarter. Kestra Advisory Services LLC now owns 30,419 shares of the biotechnology company’s stock valued at $992,000 after purchasing an additional 3,328 shares in the last quarter. Quadcap Wealth Management LLC lifted its stake in shares of Viking Therapeutics by 43.7% in the 3rd quarter. Quadcap Wealth Management LLC now owns 8,272 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 2,514 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Viking Therapeutics by 4.2% in the 3rd quarter. Profund Advisors LLC now owns 50,459 shares of the biotechnology company’s stock valued at $1,645,000 after purchasing an additional 2,052 shares during the last quarter. Finally, Raleigh Capital Management Inc. lifted its stake in shares of Viking Therapeutics by 371.4% in the 3rd quarter. Raleigh Capital Management Inc. now owns 2,305 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 1,816 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company develops therapies for metabolic and endocrine disorders, with a focus on conditions involving obesity, nonalcoholic steatohepatitis (NASH), and other liver and lipid disorders.

Viking’s lead program is VK2735, an investigational dual GLP-1/GIP receptor agonist being developed in injectable and oral formulations for obesity and related metabolic conditions.